The DOI matches its Crossref record; 36 of the 37 references it cites were found in a registry or an index.
Increased 5α-Reductase Activity and Adrenocortical Drive in Women with Polycystic Ovary Syndrome
Abstract
CONTEXT: Polycystic ovary syndrome (PCOS) is characterized by hyperandrogenism, anovulation, and susceptibility to the metabolic syndrome. Altered peripheral cortisol metabolism has been reported in PCOS, but also in simple obesity. OBJECTIVE: The aim of the study was to describe cortisol metabolism and metabolic characteristics of a large PCOS cohort and to delineate the effect of obesity by comparison to body mass index (BMI)-matched controls. DESIGN AND SETTING: We conducted an observational, cross-sectional study at outpatient clinics of two secondary/tertiary care centers. PATIENTS OR OTHER PARTICIPANTS: A total of 178 PCOS patients fulfilling Rotterdam criteria and 100 BMI-matched controls participated in the study. INTERVENTION: The study included 24-h urine collection for steroid metabolite excretion and fasting blood samples, followed by an oral glucose tolerance test. MAIN OUTCOME MEASURES: We measured urinary steroid metabolites including glucocorticoids and androgens and the ratios reflecting enzymatic activities involved in peripheral cortisol and androgen metabolism, 5 alpha-reductase, and 11 beta-hydroxysteroid dehydrogenase types 1 and 2. We also measured circulating levels of glucose, insulin, dehydroepiandrosterone, dehydroepiandrosterone sulfate, and testosterone and calculated homeostasis model assessment. RESULTS: Total androgen metabolites were higher in PCOS patients compared to BMI-matched controls (4,105 +/- 2,047 vs. 2,532 +/- 1,610 microg/24 h for the nonobese; 5,547 +/- 2,911 vs. 2,468 +/- 1,794 microg/24 h for the obese; both P < 0.001). Total glucocorticoid metabolites were higher in obese PCOS vs. controls (10,786 +/- 3,852 vs. 8,834 +/- 4,487 microg/24 h; P = 0.001). 5 alpha-Reductase activity correlated with BMI, insulin levels, and homeostasis model assessment. Both obese and nonobese PCOS patients had higher 5 alpha-reductase activity than controls (all P < 0.05). 11 beta-Hydroxysteroid dehydrogenase activities did not differ between PCOS and controls. CONCLUSIONS: PCOS is associated with enhanced androgen and cortisol metabolite excretion and increased 5 alpha-reductase activity that cannot be explained by obesity alone. Increased adrenal corticosteroid production represents an important pathogenic pathway in PCOS.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Systemic upregulation of 5α-reductase activity is observed in women with PCOS leading to enhanced glucocorticoid clearance and enhanced androgen activation in peripheral tissues (Fassnacht et al., 2003, Stewart et al., 1990, Vassiliadi et al., 2009)”
From Intracrine androgen biosynthesis, metabolism and action revisited (2018) · cites this paper as Vassiliadi et al., 2009
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
(2004) · Fertility and Sterility · doi:10.1016/j.fertnstert.2003.10.004 · Cited by 9,050
Men at risk: occupation and male infertility.
Claman, P. (2004) · Fertility and Sterility · doi:10.1016/s0015-0282(03)01188-9 · Cited by 2,219
Ehrmann, D. A. (2005) · New England Journal of Medicine · doi:10.1056/nejmra041536 · Cited by 1,920
Asunción, M., Calvo, R. M., Millán, J. L. S., Sancho, J., Ávila, S., & Escobar-Morreale, H. F. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.85.7.6682 · Cited by 1,328
Diamanti‐Kandarakis, E., Kouli, C., Bergiele, A. T., Filandra, F. A., Tsianateli, T. C., Spina, G., Zapanti, E. D., & Bartzis, M. I. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.11.6148 · Cited by 1,107
Correlation of Hyperandrogenism with Hyperinsulinism in Polycystic Ovarian Disease*
Burghen, G. A., Givens, J. R., & Kitabchi, A. E. (1980) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-50-1-113 · Cited by 919
Asuncion, M. (2000) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.85.7.2434 · Cited by 791
Tissue-Specific Dysregulation of Cortisol Metabolism in Human Obesity
Rask, E., Olsson, T., Söderberg, S., Andrew, R., Livingstone, D. E. W., Johnson, O., & Walker, B. R. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.3.7453 · Cited by 657
Stewart, P. M., Boulton, A., Kumar, S., Clark, P. M. S., & Shackleton, C. H. L. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.3.5538 · Cited by 398
Livingstone, D. E. W., Jones, G. C., Smith, K., Jamieson, P. M., Andrew, R., Kenyon, C. J., & Walker, B. R. (2000) · Endocrinology · doi:10.1210/endo.141.2.7297 · Cited by 354
Obesity and Gender Influence Cortisol Secretion and Metabolism in Man
Andrew, R., Phillips, D. I. W., & Walker, B. R. (1998) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.83.5.4951 · Cited by 351
Jamieson, P. M., Chapman, K. E., Edwards, C. R. W., & Seckl, J. R. (1995) · Endocrinology · doi:10.1210/endo.136.11.7588203 · Cited by 301
Urinary free cortisone and the assessment of 11β‐hydroxysteroid dehydrogenase activity in man
Palermo, M., Shackleton, C. H. L., Mantero, F., & Stewart, P. M. (1996) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1996.00853.x · Cited by 276
Berger, J. P., Tanen, M. R. L., Elbrecht, A., Hermanowski‐Vosatka, A., Moller, D. E., Wright, S. D., & Thieringer, R. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m003592200 · Cited by 208
Rodin, A., Thakkar, H., Taylor, N., & Clayton, R. N. (1994) · New England Journal of Medicine · doi:10.1056/nejm199402173300703 · Cited by 191
5 α-reductase activity in polycystic ovary syndrome
Stewart, P. M., Edwards, C. R. W., Shackleton, C. H. L., & Beastall, G. H. (1990) · The Lancet · doi:10.1016/0140-6736(90)90664-q · Cited by 189
Fassnacht, M., Schlenz, N., Schneider, S. B., Wudy, S. A., Allolio, B., & Arlt, W. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021875 · Cited by 158
Self-citationTsilchorozidou, T., Honour, J. W., & Conway, G. S. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030240 · Cited by 155
Tomlinson, J., Finney, J., Gay, C., Hughes, B. A., Hughes, S. V., & Stewart, P. M. (2008) · Diabetes · doi:10.2337/db08-0495 · Cited by 132
5 -Reductase Activity in Women with Polycystic Ovary Syndrome
Jakimiuk, A. J., Weitsman, S. R., & Magoffin, D. A. (1999) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.84.7.5863 · Cited by 102
Tomlinson, J. W., Finney, J., Hughes, B. A., Hughes, S. V., & Stewart, P. M. (2008) · Diabetes · doi:10.2337/db08-0094 · Cited by 91
Self-citationGoodarzi, M. O., Shah, N. A., Antoine, H. J., Pall, M., Guo, X., & Azziz, R. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0227 · Cited by 90
Gambineri, A., Vicennati, V., Genghini, S., Tomassoni, F., Pagotto, U., Pasquali, R., & Walker, B. R. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2222 · Cited by 75
Walker, E. A., Ahmed, A., Lavery, G. G., Tomlinson, J., Kim, S. Y., Cooper, M. S., Ride, J. P., Hughes, B. A., Shackleton, C. H. L., McKiernan, P. J., et al. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m704144200 · Cited by 60
Hyperandrogenism in Polycystic Ovary Syndrome
Rodin, A., Thakkar, H., Taylor, N., & Clayton, R. N. (1994) · Obstetrical & Gynecological Survey · doi:10.1097/00006254-199407000-00021 · Cited by 51
Holt, H. B., Wild, S. H., Postle, A. D., Zhang, J., Koster, G., Umpleby, M., Shojaee-Moradie, F., Dewbury, K., Wood, P. J., Phillips, D. I., et al. (2007) · Diabetologia · doi:10.1007/s00125-007-0629-9 · Cited by 48
Chin, D., Shackleton, C. H. L., Prasad, V., Kohn, B., David, R., Imperato‐McGinley, J., Cohen, H., McMahon, D. J., & Oberfield, S. E. (2000) · Journal of Pediatric Endocrinology and Metabolism · doi:10.1515/jpem.2000.13.3.253 · Cited by 46
Kerstens, M. N., Riemens, S. C., Sluiter, W. J., Pratt, J. J., Wolthers, B. G., & Dullaart, R. P. F. (2000) · Clinical Endocrinology · doi:10.1046/j.1365-2265.2000.00975.x · Cited by 43
Gu, S., Ripp, S. L., Prough, R. A., & Geoghegan, T. E. (2003) · Molecular Pharmacology · doi:10.1124/mol.63.3.722 · Cited by 34
Scanlon, M. J., Whorwood, C. B., Franks, S., Reed, M. J., & James, V. H. T. (1988) · Clinical Endocrinology · doi:10.1111/j.1365-2265.1988.tb03702.x · Cited by 31
Adrenal involvement in polycystic ovary syndrome
Gonzalez, F. (1997) · Seminars in Reproductive Medicine · doi:10.1055/s-2007-1016296 · Cited by 30
Glintborg, D., Hermann, A. P., Hagen, C., Jensen, L. T., Frystyk, J., Bennett, P., Flyvbjerg, A., & Andersen, M. (2008) · Fertility and Sterility · doi:10.1016/j.fertnstert.2007.12.082 · Cited by 25
Increased A‐ring Reduction of Glucocorticoids in Obese Zucker Rats: Effects of Insulin Sensitization
Livingstone, D. E. W., McInnes, K. J., Walker, B. R., & Andrew, R. (2005) · Obesity Research · doi:10.1038/oby.2005.186 · Cited by 23
Skałba, P., Dąbkowska-Huć, A., Kazimierczak, W., Samojedny, A., Paul-Samojedny, M., & Chełmicki, Z. (2006) · Clinical and Experimental Dermatology · doi:10.1111/j.1365-2230.2006.02146.x · Cited by 23
Silfen, M. E., Shackleton, C. H. L., Manibo, A. M., Levine, L. S., Sekhar, D. L., McMahon, D. J., & Oberfield, S. E. (2002) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2001-012045 · Cited by 10
Cited by
Sorted by citations
Rosenfield, R. L., & Ehrmann, D. A. (2016) · Endocrine Reviews · doi:10.1210/er.2015-1104 · Cited by 1,603
The polycystic ovary syndrome: a position statement from the European Society of Endocrinology
Conway, G., Dewailly, D., Diamanti-Kandarakis, E., Escobar-Morreale, H. F., Franks, S., Gambineri, A., Kelestimur, F., Macut, D., Micic, D., Pasquali, R., et al. (2014) · European Journal of Endocrinology · doi:10.1530/eje-14-0253 · Cited by 676
Self-citationObesity and polycystic ovary syndrome
Barber, T. M., & Franks, S. (2021) · Clinical Endocrinology · doi:10.1111/cen.14421 · Cited by 385
Obesity and Polycystic Ovary Syndrome: Implications for Pathogenesis and Novel Management Strategies
Barber, T. M., Hanson, P., Weickert, M. O., & Franks, S. (2019) · Clinical Medicine Insights: Reproductive Health · doi:10.1177/1179558119874042 · Cited by 411
O’Reilly, M., TAYLOR, A. E. R., Crabtree, N. J., Hughes, B. A., Capper, F., Crowley, R. K., Stewart, P. M., Tomlinson, J., & Arlt, W. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3399 · Cited by 279
Metadata
- Authors
- Vassiliadi, D. A., Barber, T. M., Hughes, B. A., McCarthy, M. I., Wass, J. A. H., Franks, S., Nightingale, P., Tomlinson, J. W., Arlt, W., & Stewart, P. M.
- Affiliations
- University of Birmingham (GB)
- University of Oxford (GB)
- Imperial College London (GB)
- National Health Service (GB)
- Corresponding author
- Stewart, Paul M.
- ORCID
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 2009-09-01
- Volume
- 94
- Issue
- 9
- Pages
- 3558-3566
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2153159631
- Cited by
- 110
- References
- 37
- Citations by year
- 2025: 5 · 2024: 3 · 2023: 5 · 2022: 6 · 2021: 4 · 2020: 7 · 2019: 7 · 2018: 5 · 2017: 9 · 2016: 13 · 2015: 9 · 2014: 13 · 2013: 4 · 2012: 5
- FWCI
- 7.39
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Funders
- Wellcome Trust (082809/Z/07/Z, 075322/Z/04/Z)
- National Institute for Health and Care Research (NF-SI-0508-10356)
- Novo Nordisk UK Research Foundation
- University of Oxford
- Novo Nordisk
- Medical Research Council
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Ovarian function and disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adrenal Hormones and Disorders
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Sexual Differentiation and Disorders
- Keywords
- polycystic ovary syndrome, 5alpha-reductase activity, 11β-hydroxysteroid dehydrogenase, cortisol metabolism, glucocorticoid metabolism, androgen metabolism, obesity, hyperandrogenism, insulin resistance, HOMA, urinary steroid metabolites, dehydroepiandrosterone sulfate, dehydroepiandrosterone
- MeSH terms
- Adolescent, Adult, Androgens, Cross-Sectional Studies, Female, Glucocorticoids, Humans, Hydrocortisone, Middle Aged, Obesity, Polycystic Ovary Syndrome, Cholestenone 5 alpha-Reductase
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review